We are currently setting up a research and clinical structure to offer cellular treatment for patients with cancer with a strong pre-clinical and clinical interaction i) to better understand the tumor-host relationship, ii) to map the patients ‘private’ mutational burden and iii) to identify the best immunological strategy to fight off cancer using molecular methods, gene transfer, biological therapy guided by imaging technologies. Data from infectious diseases aid to better understand the tumor-host relationship and aid to gauge biologically and clinically relevant HDTs (host directed therapy) concepts.